MESO Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (24 Apr 2024 @ 16:00):

Mesoblast Limited, a biopharmaceutical company, develops and commercializes allogeneic cellular medicines in the United States, Australia, Singapore, the United Kingdom, and Switzerland...

Stats
Today's Volume	198 154
Average Volume	2.25M
Market Cap	709.85M
EPS	$0 ( 2024-03-25 )
Next earnings date	( $0 ) 2024-05-23
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-7.15
ATR14	$0.0120 (0.19%)

Volume Correlation

Long: -0.03 (neutral)

Short: 0.70 (moderate)

Signal:(68.402) Neutral

Mesoblast Limited Correlation

10 Most Positive Correlations

10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Mesoblast Limited Correlation - Currency/Commodity

0.25
( neutral )

0.27
( neutral )

0.00
( neutral )

0.10
( neutral )

0.69
( moderate )

0.17
( neutral )

Mesoblast Limited Financials

Annual	2023
Revenue:	$7.50M
Gross Profit:	$-20.23M (-269.72 %)
EPS:	$-1.050

Q2	2024
Revenue:	$1.69M
Gross Profit:	$-8.00M (-472.40 %)
EPS:	$-0.0191

Q1	2024
Revenue:	$1.69M
Gross Profit:	$-8.00M (-472.40 %)
EPS:	$-0.0191

Q4	2023
Revenue:	$2.14M
Gross Profit:	$-6.59M (-307.99 %)
EPS:	$-0.280

Financial Reports:

No articles found.

Mesoblast Limited

Mesoblast Limited, a biopharmaceutical company, develops and commercializes allogeneic cellular medicines in the United States, Australia, Singapore, the United Kingdom, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells. The company's products under the Phase III clinical trials include remestemcel-L for the treatment of steroid refractory acute graft versus host disease, as well as acute respiratory distress syndrome due to COVID-19 infection; Rexlemestrocel-L to treat advanced chronic heart failure; and MPC-06-ID for chronic low back pain due to degenerative disc disease. It is also developing MPC-300-IV for the treatment of biologic refractory rheumatoid arthritis diabetic nephropathy. The company has strategic partnerships with Tasly Pharmaceutical Group to offer MPC-150-IM for heart failure and MPC-25-IC for heart attacks in China; JCR Pharmaceuticals Co. Ltd. for the treatment of wound healing in patients with epidermolysis bullosa; and Grünenthal to develops and commercializes cell therapy for the treatment of chronic low back pain. Mesoblast Limited was incorporated in 2004 and is headquartered in Melbourne, Australia.